文献速递脊柱关节炎

早期治疗脊柱关节炎是否重要:系统文献综述结果

Treating spondyloarthritis early: does it matter? Results from a systematic literature review.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

以症状持续时间<5年定义早期时,非放射学中轴型脊柱关节炎早期治疗与更好结局相关,但证据非常有限;以疾病病程或影像学损伤定义早期时,各组间无差异。

要点

  • 以症状持续时间<5年定义早期时,非放射学中轴型脊柱关节炎早期治疗与更好结局相关,证据非常有限。
  • 在随机对照试验中,非放射学中轴型脊柱关节炎ASAS40相对风险比为5.24(95%CI 1.12, 24.41)和1.52(0.60, 3.87)。
  • 以疾病病程或影像学损伤定义早期时,各组间治疗反应无差异。

核心结论

  • 支持早期中轴型脊柱关节炎结局更好的证据非常有限,且仅限于非放射学中轴型脊柱关节炎和症状持续时间<5年。
  • 当早期中轴型脊柱关节炎基于疾病病程或影像学损伤定义时,未发现治疗反应差异。

研究设计与样本

  • 21项研究基于症状持续时间(n=6)或疾病病程(n=15)比较组间差异,7项研究基于影像学损伤有无比较(其中2项研究使用两种比较)。
  • 对分类结局计算相对风险、相对风险比和需治疗人数,对连续结局计算双重差分,以比较基于症状/疾病病程或影像学损伤有无分层的组间差异。

主要发现

  • 在随机对照试验中,以症状持续时间<5年定义早期时,非放射学中轴型脊柱关节炎早期治疗与更好结局相关(n=2,ASAS40相对风险比5.24(95%CI 1.12, 24.41)和1.52(0.60, 3.87))。
  • 在随机对照试验中,以症状持续时间<5年定义早期时,放射学中轴型脊柱关节炎早期治疗与更好结局无关(n=1,ASAS20 0.96(95%CI 0.53-1.73))。
  • 当早期中轴型脊柱关节炎基于疾病病程或影像学损伤定义时,各组间未发现差异。

关键数值与推荐

  • 早期中轴型脊柱关节炎以症状持续时间<5年定义时,非放射学中轴型脊柱关节炎ASAS40相对风险比为5.24(95%CI 1.12, 24.41)和1.52(0.60, 3.87)(n=2)。
  • 早期中轴型脊柱关节炎以症状持续时间<5年定义时,放射学中轴型脊柱关节炎ASAS20为0.96(95%CI 0.53-1.73)(n=1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 支持早期中轴型脊柱关节炎结局更好的证据非常有限,且仅限于非放射学中轴型脊柱关节炎和症状持续时间<5年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To summarize evidence on the relationship between early treatment (definition based on symptom/disease duration or radiographic damage) and treatment clinical response in patients with SpA. METHODS: A systematic literature review was conducted in studies on SpA patients treated with NSAIDs or biological/targeted synthetic DMARDs addressing the impact of symptom/disease duration or presence of radiographic damage on treatment response assessed by any disease activity outcome. For categorical outcomes, relative risk, relative risk ratio and number needed to treat were calculated, and for continuous outcomes, differences in differences, to compare groups stratified based on symptom/disease duration or the presence of radiographic damage. RESULTS: From the 8769 articles retrieved, 25 were included and 2 added by hand-search, all in axial SpA (axSpA), most of them with low risk of bias. Twenty-one studies compared groups based on symptom duration (n = 6) or disease duration (n = 15) and seven studies based on absence/presence of radiographic damage (two studies used two comparisons). When early axSpA was defined by symptom duration (<5 years) in randomized controlled trials, early treatment was associated with better outcomes in patients with non-radiographic axSpA [n = 2, ASAS40 relative risk ratio 5.24 (95% CI 1.12, 24.41) and 1.52 (0.60, 3.87)] but not in radiographic axSpA (n = 1) [ASAS20 0.96 (0.53-1.73)]. When early axSpA was defined based on disease duration or radiographic damage, no differences were found between groups. CONCLUSION: Evidence towards better outcomes in early axSpA is very limited and restricted to non-radiographic axSpA and <5 years symptom duration. When early axSpA is defined based on disease duration or radiographic damage, no differences in response to treatment are found.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Capelusnik D, Benavent D, van der Heijde D, et al. Treating spondyloarthritis early: does it matter? Results from a systematic literature review. Rheumatology (Oxford). 2023. PMID: 36099043. doi:10.1093/rheumatology/keac532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。